Review
Research progress on the efficacy and safety of PARP inhibitors in mCRPC
Liu Hao, Tang Pengtao, Huang Jian
Published 2023-07-15
Cite as Chin J Urol, 2023, 44(7): 551-554. DOI: 10.3760/cma.j.cn112330-20221121-00623
Abstract
Poly ADP-ribose polymerase (PARP) inhibitors are novel agents for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in recent years, and a variety of PARP inhibitors have been reported with clinical evidence for the beneficial. Although these drugs are actually of attributes with pharmacological similarities, due to the discrepancies in the molecular structure and pharmacodynamics, the respective efficacy and safety from clinical circumstances are quite varied. While it comes to the best clinical determination, the optimization for regimen is important on the basis of clinical exhaustiveness for the reports, in addition the laboratory examination for mCRPC, and either the tumorous genetic benchmark are necessarily being calculated.
Key words:
Prostatic neoplasms; Carcinoma; Metastatic; Castration-resistant; Poly ADP-ribose polymerase inhibitors; Efficacy; Safety
Contributor Information
Liu Hao
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
Tang Pengtao
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
Huang Jian
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China